In another deal to strengthen its cardiovascular franchise, Merck & Co has signed an exclusive deal to develop and market Portola Pharmaceuticals’ betrixaban, a Factor Xa inhibitor. Betrixaban is currently in Phase II trials for the prevention of stroke in patients with atrial fibrillation.